SquamousCellCarcinomaofSkin near Forest Hills, NY

Biography: Meghna S. Trivedi, MD, MS cares for patients diagnosed with breast cancer. Dr. Trivedi received her medical degree from the University of Maryland School of Medicine, and completed her residency at the University of Pennsylvania. She went on to complete her fellowship in hematology/oncology at Columbia University. Dr. Trivedi co-leads the Hereditary Breast and Ovarian Cancer Program, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi's research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. Dr. Trivedi is a member of the American Society of Clinical Oncologists and SWOG.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Originally from Columbus, OH, SunilIyercompleted his undergraduate studies at Washington University in St. Louis. He then completed his medical education and training at the University of Miami, where he served as chief hematology/oncology fellow. He has a strong interest in leukemia, particularly in the genomics and treatment of acute lymphoblastic leukemia.

Biography: Dr. Lentzsch is a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital. She received her medical and doctorate degrees from Humboldt University in Berlin, Germany, where she also completed her residency and fellowship. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA. Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia. Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Biography: Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract.As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick's clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These effortsentail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events fromimmunotherapy.